AFMD - Affimed shares gain 5% on encouraging AFM24 data in EGFR-expressing solid tumors

Affimed (AFMD) announces pre-clinical data on its Innate Cell Engager ((ICE)) AFM24 as monotherapy and in combination with adoptively transferred NK cells at AACR Meeting 2021. AFM24 induces NK cell-mediated antibody-dependent cellular cytotoxicity ((ADCC)) against EGFR-expressing tumor cells even in the presence of competing IgG and can induce potent cell killing in tumors independent of KRAS mutations. In addition, data from a xenograft mouse model demonstrate that AFM24 in combination with NK cells results in dose-dependent tumor regression. “AFM24’s novel mechanism of action is independent of EGFR signaling and has the potential to change the treatment paradigm for EGFR-expressing solid tumors,” said Dr. Arndt Schottelius, Affimed’s Chief Scientific Officer. In February 2020, Affimed collaborated with Roche to explore the combination of AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).AFMD shares up 5.5% premarket trading at $10.31.

For further details see:

Affimed shares gain 5% on encouraging AFM24 data in EGFR-expressing solid tumors